scholarly journals Long-term local control rates of patients with adenoid cystic carcinoma of the head and neck managed by surgery and postoperative radiation

2017 ◽  
Vol 127 (10) ◽  
pp. 2265-2269 ◽  
Author(s):  
Safina Ali ◽  
Frank L. Palmer ◽  
Nora Katabi ◽  
Nancy Lee ◽  
Jatin P. Shah ◽  
...  
Keyword(s):  
Adenoid Cystic Carcinoma ◽  
Head And Neck ◽  
Local Control ◽  
Postoperative Radiation ◽  
Adenoid Cystic

scholarly journals Long-Term Outcomes of Personalized Stereotactic Ablative Brachytherapy for Recurrent Head and Neck Adenoid Cystic Carcinoma after Surgery or External Beam Radiotherapy: A 9-Year Study

2021 ◽  
Vol 11 (9) ◽  
pp. 839
Author(s):  
Yi Chen ◽  
Jinzhao Dai ◽  
Yuliang Jiang ◽  
Zhe Ji ◽  
Ping Jiang ◽  
...  
Keyword(s):  
Adenoid Cystic Carcinoma ◽  
Head And Neck ◽  
Local Control ◽  
External Beam Radiotherapy ◽  
Objective Response ◽  
External Beam ◽  
Long Term Outcomes ◽  
Adenoid Cystic ◽  
Recurrent Head

The management of recurrent head and neck adenoid cystic carcinoma (HNACC) remains a problematic challenge. This study aims to evaluate the long-term outcomes of personalized stereotactic ablative brachytherapy (SABT) as a salvage treatment for recurrent HNACC after surgery or external beam radiotherapy (EBRT). 21 patients with recurrent HNACC after surgery or EBRT successfully underwent iodine-125 (I-125) seed SABT from May 2011 to November 2019. The objective response rate (ORR), disease control rate (DCR), local control time (LCT), overall survival (OS), symptomatic relief and adverse events (AEs) were analyzed. Following SABT, the ORR and DCR were 85.7% and 100%, respectively. The 3-, and 5-year LCT rates were 68.8% and 55.1%, respectively, and the 3- and 5-year OS rates were 85.9% and 66.2%, respectively. Furthermore, univariate analyses showed that higher D90 (>137.1 Gy) was a strong positive prognostic factor of LCT (p < 0.05). The pain disappeared in one patient 3 months after SABT and partial pain improvement was observed in nine patients 1 to 6 months after SABT. Additionally, dyspnea was relieved in one patient with the tumor involving the trachea. The major AEs were mild intraoperative hemorrhage and skin/mucosal toxicities which were generally graded ≤2 and well-tolerated. Personalized SABT was an effective and safe alternative option for recurrent HNACC after the previous failure of surgery or EBRT. The parameter of D90 may influence the local control.

scholarly journals The Potential Prognostic Value of a Novel Hematologic Marker Fibrinogen-to-Lymphocyte Ratio in Head and Neck Adenoid-Cystic Carcinoma

2021 ◽  
Vol 11 (11) ◽  
pp. 1228
Author(s):  
Faris F. Brkic ◽  
Stefan Stoiber ◽  
Marlene Friedl ◽  
Tobias Maier ◽  
Gregor Heiduschka ◽  
...  
Keyword(s):  
Adenoid Cystic Carcinoma ◽  
Head And Neck ◽  
Disease Free Survival ◽  
Threshold Value ◽  
Late Recurrence ◽  
Study Cohort ◽  
Lymphocyte Ratio ◽  
Adenoid Cystic ◽  
Long Term Survivors

Many patients with adenoid-cystic carcinoma (ACC) experience an indolent course of disease over many years but face late recurrence, and long-term survivors are rare. Due to its infrequent occurrence, it is hard to predict outcome in these patients. The fibrinogen-to-lymphocyte ratio (FLR) was recently proposed as an outcome prognosticator in different cancer entities. We aimed to investigate its prognostic relevance in patients with head and neck ACC. This retrospective analysis was performed including all patients treated for ACC between 1998 and 2020. The FLR ratio was calculated based on pretreatment values (0–7 days). The study cohort was dichotomized based on optimized threshold value and compared for differences in outcome (overall survival (OS) and disease-free survival (DFS)). In the cohort of 39 included patients, the OS was significantly longer in the low (n = 28) compared to the high pretreatment FLR group (n = 11) (median OS 150.5 months, 95% confidence intervals (CI) 85.3–215.7 months vs. 29.4 months, 95% CI not reached; p = 0.0093). Similarly, the DFS was significantly longer in the low FLR group (median DFS 74.5 months, 95% CI 30.6–118.4 months vs. 11.0 months, 95% CI 5.1–16.9 months; p = 0.019). The FLR is an easily obtainable and simple marker and may be a valuable outcome prognosticator in patients with ACC. Further studies are needed for validation of our results.

scholarly journals Adenoid cystic Carcinoma and Carbon ion Only irradiation (ACCO): Study protocol for a prospective, open, randomized, two-armed, phase II study

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Kristin Lang ◽  
Sebastian Adeberg ◽  
Semi Harrabi ◽  
Thomas Held ◽  
Meinhard Kieser ◽  
...  
Keyword(s):  
Adenoid Cystic Carcinoma ◽  
Head And Neck ◽  
Phase Ii ◽  
Local Control ◽  
Carbon Ion Radiotherapy ◽  
Carbon Ions ◽  
Node Negative ◽  
Carbon Ion ◽  
Adenoid Cystic ◽  
High Let

Abstract Background Adenoid cystic carcinoma is a rare form of head and neck cancer with a slow, but aggressive growth pattern which remains a challenge for local tumor control. Based on phase II data, radiation treatment using partially high LET radiation results in a prolonged PFS and OS. There is a paucity of randomized clinical data examining the role of the use of high LET radiation only. Therefore, the purpose of this prospective clinical trial is to analyze local control rates in patients with node negative ACC treated with carbon ion radiotherapy alone compared to a combined modality approach. Methods This trial is conducted as a prospective, open-label, phase II, two-armed, investigator-initiated study comparing the local control rates in node negative ACCs of the head and neck treated either with sole carbon ion radiotherapy or a combination of carbon ions and photons. Secondary outcomes investigated are progression-free survival, overall survival, acute and late toxicity, and quality of life. A total of 314 patients will be randomly assigned to C12 treatment alone or bimodal treatment: Patients in the experimental group will receive a dose of 51 Gy (RBE) in 17 fractions and a boost of 15 Gy (RBE) in 5 fractions. Patients in the control group will receive 25 fractions photon IMRT 50Gy and a boost using 8 × 3 Gy (RBE) carbon ions. Local control will be assessed in regular follow up examinations until 5 years after the completion of treatment. Discussion The present trial aims to evaluate local control rates to compare sole carbon ion radiotherapy to bimodal radiotherapy with carbon ions and photons in patients with node negative ACCs of the head and neck region. Local control is selected as the primary endpoint due to its major clinical relevance because of slow but aggressive growth patterns. Trial registration The study was prospectively registered on 2nd January 2020: ClinicalTrials.gov, NCT04214366. “Adenoid Cystic Carcinoma and Carbon Ion Only Irradiation (ACCO)”. Study status Under recruitment, participant recruitment is not completed. Start of recruitment was January 2020. There are no results been published or submitted to any journal.

Long-term local control of recurrent adenoid cystic carcinoma in the parotid gland with radiotherapy and intraarterial infusion chemotherapy

2006 ◽  
Vol 24 (4) ◽  
pp. 287-291 ◽  
Author(s):  
Koutarou Terashima ◽  
Yoshiyuki Shioyama ◽  
Katsumasa Nakamura ◽  
Saiji Ohga ◽  
Satoshi Nomoto ◽  
...  
Keyword(s):  
Parotid Gland ◽  
Adenoid Cystic Carcinoma ◽  
Local Control ◽  
Intraarterial Infusion ◽  
Infusion Chemotherapy ◽  
Adenoid Cystic

Role for Postoperative Radiation Therapy in Adenoid Cystic Carcinoma of the Head and Neck

2004 ◽  
Vol 114 (7) ◽  
pp. 1194-1199 ◽  
Author(s):  
Damon A. Silverman ◽  
Thomas P. Carlson ◽  
Deepak Khuntia ◽  
Richard T. Bergstrom ◽  
Jerrold Saxton ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Adenoid Cystic Carcinoma ◽  
Head And Neck ◽  
Postoperative Radiation ◽  
Postoperative Radiation Therapy ◽  
Adenoid Cystic
Sign in / Sign up

Export Citation Format

Share Document